EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Approach to Weight Loss in Women Over 50 Years: Insights from RESET Study with a Shape-Shifting Hydrogel Capsule

Gitanjali Srivastava, Yael Kenan, Michael Krychman, Angela Golden, Barbara Dehn, Liora Cohen Asaraf, Dror Diker

Diabetes Technology and Obesity Medicine · 01.03.2025 · 1 (1)

DOI: 10.1177/29986702251408809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology and Obesity Medicine, online erschienen am 09.03.2026. Verfasst von Gitanjali Srivastava und 6 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Women over the age of 50 often experience weight gain due to menopausal-related hormonal changes, increasing their risk for health complications. The Epitomee capsule, a nondrug medical device designed to enhance satiety, may offer significant benefits for weight loss in this demographic.

Methods

This sub-analysis of the Randomized Evaluation of Efficacy and Safety of the Epitomee Capsule Trial (RESET) double-blind placebo-controlled study included 104 women aged ≥50, randomized to Epitomee capsule ( n = 52) or placebo ( n = 52) with lifestyle counseling. Outcomes included % weight loss (baseline to week 24), responder rates (≥5%, ≥10%, ≥15%), body mass index (BMI) change, early responder, waist circumference, and glycemic status.

Results

Age and gender were not significant covariates influencing Epitomee capsule efficacy in the multivariate model of the RESET study. Among women aged ≥50 years, average weight reduction was 7.6% in the Epitomee group versus 4.4% in the placebo group ( P = 0.0287). Significantly more women treated with Epitomee achieved ≥5% weight loss (63% vs 42%, P = 0.0463), and ≥10% weight loss (29% vs 9%, P = 0.0169). Among women aged older than 50 years, early response (ER) was defined as a weight loss of ≥2% at week 8. ER, average weight reduction at week 24 was 9.9% of baseline body weight in the Epitomee group versus 6.2% in the placebo group ( P = 0.0074). The Epitomee group also showed greater reductions in BMI and waist circumference, along with more frequent shifts toward normoglycemia. Among women >50 years, a significantly greater proportion improved their BMI category compared with placebo (56% vs 21%, P = 0.0007). Adverse event rates were similar between groups, and no serious events occurred.

Conclusions

The Epitomee capsule demonstrates significant efficacy in promoting weight loss, improving BMI, and a showing trend toward improved metabolic parameters in women over the age of 50, with a favorable safety profile, suggesting its potential as a valuable nonpharmaceutical intervention for the menopausal population.

Zitieren

APA

Srivastava, G., Kenan, Y., Krychman, M., Golden, A., Dehn, B., Asaraf, L. C., & Diker, D. (2025). A Novel Approach to Weight Loss in Women Over 50 Years: Insights from RESET Study with a Shape-Shifting Hydrogel Capsule. Diabetes Technology and Obesity Medicine, 1(1). https://doi.org/10.1177/29986702251408809

Vancouver

Srivastava G, Kenan Y, Krychman M, Golden A, Dehn B, Asaraf LC, et al. A Novel Approach to Weight Loss in Women Over 50 Years: Insights from RESET Study with a Shape-Shifting Hydrogel Capsule. Diabetes Technology and Obesity Medicine. 2025;1(1). doi:10.1177/29986702251408809

BibTeX
@article{Srivastava2025,
  author = {Srivastava, Gitanjali and Kenan, Yael and Krychman, Michael and Golden, Angela and Dehn, Barbara and Asaraf, Liora Cohen and Diker, Dror},
  title = {A Novel Approach to Weight Loss in Women Over 50 Years: Insights from RESET Study with a Shape-Shifting Hydrogel Capsule},
  journal = {Diabetes Technology and Obesity Medicine},
  year = {2025},
  volume = {1},
  number = {1},
  doi = {10.1177/29986702251408809}
}
Kostenlos starten →